^
Association details:
| Biomarker: | AKT1 E17K |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) + vevorisertib (ARQ 751) (pan-AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
C076 - In vitro and in vivo combination of ARQ 751 with PARP inhibitors, CDK4/6 Inhibitors, Fulvestrant and Paclitaxel
Published date:
10/29/2019
Excerpt:
Furthermore, an estrogen receptor positive patient-derived tumor xenograft model harboring the AKT1-E17K mutation was used to assess the effect of ARQ 751 in combination with either fulvestrant or palbociclib or both agents. Combination of ARQ 751 at 25 mg/kg with either fulvestrant at 2.5 mg/kg or palbociclib at 50 mg/kg exerted tumor growth inhibition of 91% or 93%, respectively, as compared to 69% for ARQ 751, 68% for fulvestrant and 38% for palbociclib. When the three agents were combined, tumor regression (TGI >100%) was observed.
Secondary therapy:
fulvestrant
